Headlands Technologies LLC Acquires 28,473 Shares of Boston Scientific Corporation $BSX

Headlands Technologies LLC raised its holdings in Boston Scientific Corporation (NYSE:BSX) by 146.2% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,955 shares of the medical equipment provider’s stock after buying an additional 28,473 shares during the period. Headlands Technologies LLC’s holdings in Boston Scientific were worth $5,151,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. FWL Investment Management LLC acquired a new stake in Boston Scientific during the 2nd quarter valued at $26,000. Sound Income Strategies LLC grew its stake in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 120 shares during the last quarter. 1248 Management LLC bought a new position in Boston Scientific in the 1st quarter valued at about $26,000. Kilter Group LLC acquired a new stake in Boston Scientific during the second quarter worth approximately $30,000. Finally, Princeton Global Asset Management LLC bought a new stake in shares of Boston Scientific during the second quarter worth approximately $32,000. 89.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Wells Fargo & Company increased their target price on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. UBS Group increased their price objective on Boston Scientific from $135.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Barclays boosted their target price on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Leerink Partners raised their price target on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Finally, Cowen reiterated a “buy” rating on shares of Boston Scientific in a research note on Thursday. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $124.43.

Boston Scientific Stock Up 0.9%

BSX stock opened at $92.58 on Friday. Boston Scientific Corporation has a 52 week low of $85.98 and a 52 week high of $109.50. The business has a 50-day simple moving average of $98.85 and a 200 day simple moving average of $101.61. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The company has a market cap of $137.24 billion, a PE ratio of 49.51, a price-to-earnings-growth ratio of 1.86 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. The firm had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The business’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same period last year, the firm earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at $17,739,678.74. This represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. The trade was a 42.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 143,095 shares of company stock worth $14,228,950 over the last three months. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.